Avidity Partners Management LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
Avidity Partners Management LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$41,729,299
+56.5%
801,100
+58.9%
1.68%
+190.7%
Q4 2022$26,671,680
-59.1%
504,000
-64.1%
0.58%
-56.4%
Q3 2022$65,258,000
+47.4%
1,402,500
+80.9%
1.33%
+30.6%
Q2 2022$44,266,000775,5041.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders